Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | AHR | P35869 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22525916 | 0.87 | GABRA1 (0.64) | GABRA1GABRB1ALDH1A1TSHRHPGD | |
| SCHEMBL17553260 | 0.81 | ALDH1A1 (0.48) | GABRA1GABRB1ALDH1A1TSHRAHR | |
| SCHEMBL16954745 | 0.81 | ALDH1A1 (0.48) | GABRA1GABRB1ALDH1A1TSHRAHR | |
| SCHEMBL27999892 | 0.81 | ALDH1A1 (0.48) | GABRA1GABRB1ALDH1A1TSHRAHR | |
| SCHEMBL13220712 | 0.80 | GABRA1 (0.56) | GABRA1GABRB1ALDH1A1TSHRAHR | |
| SCHEMBL9603854 | 0.78 | GABRA1 (0.54) | GABRA1GABRB1ALDH1A1TSHRAHR | |
| SCHEMBL17736308 | 0.78 | GABRA1 (0.54) | GABRA1GABRB1ALDH1A1TSHRAHR | |
| SCHEMBL20314853 | 0.78 | LMNA (0.42) | GABRA1GABRB1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL18112478 | 0.77 | CYP3A4 (0.58) | GABRA1GABRB1ALDH1A1TSHRAHR | |
| SCHEMBL38660144 | 0.77 | CYP3A4 (0.58) | GABRA1GABRB1ALDH1A1TSHRAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | GABRA1 1485/4885GABRB1 1476/4885ALDH1A1 4161/4885 |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | GABRA1 2131/4885GABRB1 2311/4885ALDH1A1 4348/4885 |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | GABRA1 2462/4885GABRB1 2164/4885ALDH1A1 4385/4885 |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB4 | GABRA1 2042/4885GABRB1 2068/4885ALDH1A1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.